If you spend any time reading about functional ingredients, the words adaptogen and nootropic come up constantly, often applied to things they do not technically describe. Kava gets called both. Ashwagandha gets called a nootropic. L-theanine gets called an adaptogen. None of those are accurate. The two terms have precise definitions — each coined by a specific researcher, in a specific decade, to describe a specific type of effect. Understanding what they actually mean makes it easier to understand why a formulation that combines kava with adaptogens and nootropics is doing three distinct things at once, not the same thing three times.
Adaptogen: a Soviet-era concept with a precise definition
What Brekhman and Dardymov actually said in 1969
The term adaptogen was first used in 1947 by Soviet toxicologist Nikolai Lazarev, who described certain substances as capable of increasing an organism's non-specific resistance to stress. The term was formalized in 1969 by pharmacologists Israel Brekhman and Igor Dardymov in the Annual Review of Pharmacology — a paper that remains the reference point in the scientific literature today.
Their definition had three requirements. An adaptogen must produce a non-specific increase in resistance to a broad range of stressors — physical, chemical, and biological. It must have a normalizing effect on physiology regardless of the direction of the disturbance, meaning it should help restore balance whether the organism is running high or low on a given measure. And it must not interfere with normal physiological function more than necessary to achieve that resistance. The core idea is homeostatic support — recalibrating the body's stress-response systems rather than overriding them in one direction.
Adaptogens work primarily at the level of the hypothalamic-pituitary-adrenal (HPA) axis. This is the cascade of hormonal signaling that governs the body's response to stress — from the initial perception of a threat, through the release of corticotropin-releasing hormone and ACTH, to the eventual secretion of cortisol from the adrenal glands. In chronic stress, this axis becomes dysregulated: cortisol stays elevated, sleep degrades, immune function drops. Adaptogens appear to interrupt that dysregulation by acting on HPA signaling directly, dampening the cortisol response when it is excessive.
A substance that (1) produces a non-specific increase in resistance to multiple classes of stressor; (2) has a normalizing effect on physiology independent of the direction of disruption; and (3) does not interfere with normal function beyond what is required to produce that resistance. The operative system is the HPA axis and the body's long-term adaptive stress-response pathways.
The classical adaptogens include Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. Ashwagandha (Withania somnifera) is among the most clinically studied. Its active compounds — withanolides and sitoindosides — modulate the HPA axis, reducing cortisol secretion under chronic stress conditions. The 2012 Chandrasekhar trial found that 300 mg of full-spectrum ashwagandha root extract twice daily reduced serum cortisol by 27.9% over 60 days, versus 7.9% in the placebo group. That is a measurable shift in a biochemical stress marker — the kind of physiological-level effect Brekhman's framework specifically predicts.
What an adaptogen does not do is produce acute anxiety relief in the moment. Its effects build over weeks as cortisol load is reduced and HPA axis regulation is restored. It works upstream. That upstream position is part of what makes adaptogens useful as part of a multi-ingredient formulation rather than as stand-alone replacements for acute anxiolytics.
Nootropic: a different researcher, a different decade, a different system entirely
What Giurgea meant when he coined the term in 1972
The term nootropic comes from Romanian psychologist and chemist Corneliu Giurgea, who coined it in 1972 to describe the unusual pharmacological profile of piracetam — a compound he had been studying since the mid-1960s. Piracetam was synthesized as a potential sleep inducer. It turned out not to work for sleep. What it did instead was enhance learning and memory in animal models without producing the sedation, stimulation, or psychomotor effects that defined every existing category of psychoactive drug. Giurgea needed a new term. He combined the Greek words for mind (nous) and to bend or turn (tropein).
Giurgea's original criteria were specific. A nootropic must enhance learning and memory. It must improve the brain's resistance to disruptive conditions — hypoxia, electroconvulsive shock, chemical insult. It must protect the brain against physical and chemical damage. It must improve the efficiency of cortical control mechanisms. And crucially, it must lack the typical pharmacology of other psychotropic drugs: no sedation, no stimulation, low toxicity. That last criterion was the defining one — piracetam was cognitively enhancing and pharmacologically quiet. The two things had never appeared together in the same compound before.
A substance that (1) enhances learning and memory; (2) improves brain resistance to impairing conditions; (3) protects against physical and chemical brain injury; (4) enhances the efficacy of cortical control mechanisms; and (5) lacks the usual pharmacology of psychotropic drugs — no sedation, no stimulation, low toxicity. The mechanism is direct activation of higher integrative brain functions, particularly in memory encoding, retrieval, and executive processing.
L-theanine is a well-supported natural nootropic. It is an amino acid found almost exclusively in Camellia sinensis — the plant behind green tea — and its cognitive effects have been documented across multiple randomized trials. A 2019 double-blind, crossover trial published in Nutrients found that 200 mg of L-theanine daily in 30 healthy adults improved verbal fluency (p = 0.001) and executive function (p = 0.031) over four weeks, while simultaneously reducing trait anxiety and improving sleep quality. L-theanine modulates GABA, dopamine, and serotonin activity, reduces anxious arousal, and enhances alpha brainwave activity associated with relaxed alertness — a profile consistent with Giurgea's definition of cognitive enhancement without pharmacological noise.
In the popular wellness market, nootropic has expanded to cover almost anything that might affect brain function — caffeine, lion's mane, ginkgo, dozens of racetam variants. Most do not meet Giurgea's five criteria. The term's inflation is relevant because calling something a nootropic tells you very little without looking at the mechanism and which cognitive domains are actually affected. For the purposes of understanding a formulation, the useful question is not whether a label says nootropic, but whether the compound demonstrably and selectively improves cognitive performance without impairing normal function.
Why kava is neither
The correct category is anxiolytic, and it comes with a specific mechanism
Kava does not meet the definition of an adaptogen. It does not work on the HPA axis. It does not modulate cortisol. It does not build effects gradually over weeks. Its action is acute and GABAergic — kavalactones modulate GABA-A receptor activity in the brain within the first hour of consumption, producing relaxation and anxiety relief. The timescale, the system, and the direction of effect are all different from what Brekhman described. Calling kava an adaptogen because it reduces stress is like calling a benzodiazepine an adaptogen. The behavioral outcome overlaps, but the mechanism does not.
Kava also does not meet Giurgea's criteria for a nootropic. Its primary pharmacological effect is anxiolytic, not cognitively enhancing. Some data do show kava improving cognitive performance in anxious subjects — but that is most plausibly explained by anxiety reduction freeing up cognitive resources, not by kava directly activating higher integrative cortical function in the way Giurgea intended. The distinction matters: improving cognition by reducing a barrier to cognition is not the same as directly enhancing cognitive machinery.
The accurate term for kava is anxiolytic. Specifically, a GABAergic anxiolytic. Its active compounds — kavalactones, primarily kavain and dihydrokavain — modulate GABA-A receptor activity, with particular affinity for extrasynaptic receptor subtypes (α4β2δ) that differ from those most commonly targeted by benzodiazepines (α1β2γ2L). This distinction in receptor subtype preference is pharmacologically meaningful: it may explain why kava produces anxiolytic effects without the sedation, motor impairment, and dependence risk associated with pharmaceutical anxiolytics. Anxiolytic is not a lesser category than adaptogen or nootropic. It is the precise term for a specific pharmacological profile.
Why they work well together
Three systems, three timescales, one clear outcome
The reason these ingredient categories complement each other is that they operate on different systems with different timescales. There is no overlap between them in mechanism. Kava handles the immediate neurochemical state — GABAergic modulation producing relaxation and reduced social anxiety within an hour. Ashwagandha, taken daily over weeks, reduces the chronic cortisol load that makes situational anxiety worse to begin with. L-theanine sits between them: faster-acting than ashwagandha but more cognitively targeted than kava, keeping the mind clear and reducing the neural noise that anxious arousal generates.
Chronic stress elevates baseline cortisol, which dysregulates sleep, raises resting anxiety, and reduces the brain's capacity for clear thinking under pressure. An adaptogen like ashwagandha addresses that chronic baseline. But even with a well-regulated HPA axis, a specific social situation — a party, a conversation you care about, a room full of people you don't know — can produce acute anxious arousal. A GABAergic anxiolytic like kava handles that situational response at the level where it happens: the GABA system, in the moment. Meanwhile, the cognitive load of that same situation — staying present, responding well, not overthinking — is where a nootropic like L-theanine has its clearest effect.
The overlap in behavioral outcome — feeling calm, thinking clearly, being socially present — can make it look like all three things are doing the same job. They are not. More ashwagandha would not produce what kava produces. More kava would not reduce chronic cortisol. More L-theanine would not replace either. Each one is working on something the other two cannot reach, which is why combining them produces a better outcome than any one of them could alone.